BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37899130)

  • 1. Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine.
    Faria C; Gava F; Gravelle P; Valero JG; Dobaño-López C; Van Acker N; Quelen C; Jalowicki G; Morin R; Rossi C; Lagarde JM; Fournié JJ; Ysebaert L; Laurent C; Pérez-Galán P; Bezombes C
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target.
    Dobaño-López C; Valero JG; Araujo-Ayala F; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Arenas F; Grau M; López C; López-Oreja I; Serrat N; Martínez-Farran A; Hernández L; Playa-Albinyana H; Giménez R; Beà S; Campo E; Lagarde JM; López-Guillermo A; Magnano L; Colomer D; Bezombes C; Pérez-Galán P
    Blood Cancer J; 2024 May; 14(1):75. PubMed ID: 38697976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses.
    Araujo-Ayala F; Dobaño-López C; Valero JG; Nadeu F; Gava F; Faria C; Norlund M; Morin R; Bernes-Lasserre P; Serrat N; Playa-Albinyana H; Giménez R; Campo E; Lagarde JM; López-Guillermo A; Gine E; Colomer D; Bezombes C; Pérez-Galán P
    Leukemia; 2023 Jun; 37(6):1311-1323. PubMed ID: 37031299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of immunohistochemical expression of immune checkpoint molecules in follicular lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Shimono J; Nakashima K; Yamada K; Kawamoto K; Moritsubo M; Shimasaki Y; Inoue K; Imamoto T; Furuta T; Kohno K; Ohshima K
    Hematol Oncol; 2022 Oct; 40(4):530-540. PubMed ID: 35122292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD1 distribution pattern, regardless of the cell origin, is an independent microenvironmental prognostic factor for progression-free survival in follicular lymphoma.
    Szumera-Ciećkiewicz A; Poleszczuk J; Kuczkiewicz-Siemion O; Paszkiewicz-Kozik E; Rymkiewicz G; Sokół K; Borysiuk A; Kotarska M; Kawecka M; Owczarek D; Pytlak B; Walewski J; Prochorec-Sobieszek M
    Pathol Res Pract; 2020 Oct; 216(10):153096. PubMed ID: 32853965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling.
    Josefsson SE; Huse K; Kolstad A; Beiske K; Pende D; Steen CB; Inderberg EM; Lingjærde OC; Østenstad B; Smeland EB; Levy R; Irish JM; Myklebust JH
    Clin Cancer Res; 2018 Feb; 24(4):870-881. PubMed ID: 29217528
    [No Abstract]   [Full Text] [Related]  

  • 7. A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.
    Kastenschmidt JM; Schroers-Martin JG; Sworder BJ; Sureshchandra S; Khodadoust MS; Liu CL; Olsen M; Kurtz DM; Diehn M; Wagar LE; Alizadeh AA
    Cell Stem Cell; 2024 Mar; 31(3):410-420.e4. PubMed ID: 38402619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis.
    Sugimoto T; Watanabe T
    J Clin Exp Hematop; 2016; 56(1):1-19. PubMed ID: 27334853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.
    Myklebust JH; Irish JM; Brody J; Czerwinski DK; Houot R; Kohrt HE; Timmerman J; Said J; Green MR; Delabie J; Kolstad A; Alizadeh AA; Levy R
    Blood; 2013 Feb; 121(8):1367-76. PubMed ID: 23297127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the multi-omics landscape of follicular lymphoma.
    Xu T; Zheng Z; Zhao W
    Int J Biol Sci; 2023; 19(6):1955-1967. PubMed ID: 37063433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
    Voo KS; Foglietta M; Percivalle E; Chu F; Nattamai D; Harline M; Lee ST; Bover L; Lin HY; Baladandayuthapani V; Delgado D; Luong A; Davis RE; Kwak LW; Liu YJ; Neelapu SS
    Int J Cancer; 2014 Dec; 135(12):2834-46. PubMed ID: 24771328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis.
    Xie M; Jiang Q; Zhao S; Zhao J; Ye X; Qian W
    Int Immunopharmacol; 2020 Aug; 85():106684. PubMed ID: 32540726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry.
    Liu L; Yu X; Li Z; He X; Zha J; Lin Z; Hong Y; Zheng H; Lai Q; Ding K; Jia X; Fu G; Yu H; Yang H; Li Z; Young KH; Xu B
    J Hematol Oncol; 2022 Aug; 15(1):115. PubMed ID: 35996180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.
    Watanabe T
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
    Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
    Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
    Armand P; Janssens A; Gritti G; Radford J; Timmerman J; Pinto A; Mercadal Vilchez S; Johnson P; Cunningham D; Leonard JP; Rodig SJ; Martín-Regueira P; Sumbul A; Samakoglu S; Tang H; Ansell SM
    Blood; 2021 Feb; 137(5):637-645. PubMed ID: 32870269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm.
    Laurent C; Dietrich S; Tarte K
    Blood; 2024 Mar; 143(12):1080-1090. PubMed ID: 38096368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIGIT Expression Is Associated with T-cell Suppression and Exhaustion and Predicts Clinical Outcome and Anti-PD-1 Response in Follicular Lymphoma.
    Yang ZZ; Kim HJ; Wu H; Jalali S; Tang X; Krull JE; Ding W; Novak AJ; Ansell SM
    Clin Cancer Res; 2020 Oct; 26(19):5217-5231. PubMed ID: 32631956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass Cytometry Analysis Reveals that Specific Intratumoral CD4
    Yang ZZ; Kim HJ; Villasboas JC; Price-Troska T; Jalali S; Wu H; Luchtel RA; Polley MC; Novak AJ; Ansell SM
    Cell Rep; 2019 Feb; 26(8):2178-2193.e3. PubMed ID: 30784598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.